Catalio Capital Management, LP has filed its 13F form on February 14, 2025 for Q4 2024 where it was disclosed a total value porftolio of $457 Billion distributed in 33 stocks.
Among their holdings, we can observe that their the top five positions include companies like: Becton Dickinson & CO with a value of $33.7B, Ascendis Pharma A/S with a value of $29.7B, Bristol Myers Squibb CO with a value of $28.2B, Spring Works Therapeutics, Inc. with a value of $27.6B, and Blueprint Medicines Corp with a value of $24.8B.
Examining the 13F form we can see an increase of $457B in the current position value.
Catalio Capital Management, LP is based out at New York, NY
Below you can find more details about Catalio Capital Management, LP portfolio as well as his latest detailed transactions.
